Biotronik tapped Proximo Medical to guide the U.S. commercialization of its peripheral vascular intervention platform.
The German medtech maker’s PVI line includes the Pulsar and Astron stents, the Passeo PTA balloon catheter and Fortress introducer sheath. Castle Pines, Colo.-based Proximo provides market research services to medical device, venture capital and private equity companies.
“By partnering Biotronik’s solutions and innovations with Proximo, we accelerate our ability to help physicians deliver improved outcomes to patients,” president Ryan Walters said in prepared remarks. “At Biotronik, our focus is always on innovation that improves patient lives. We know millions of American’s suffer from peripheral artery disease and this partnership will help ensure this patient population has access to safe and effective treatment options.”
“Proximo is pleased to be partnering with Biotronik, a company committed to helping people with cardiovascular diseases live healthy, fulfilling lives,” added Proximo CEO Brett Martin. “With proven clinical data and a commitment to product excellence, this opportunity furthers our mission of putting products that save lives in the hands of physicians.”
“I was an investigator in the trial of the Biotronik Pulsar stent,” Dr. Craig Walker, president & medical director at Louisiana’s Cardiovascular Institute of the South, said in the release. “I was impressed that this stent, which has a 4F delivery system, was easy to deploy accurately and had good clinical patency. I think this will be very helpful particularly in cases where standard 5F or 6F sheaths may be occlusive.”